Bajaj Healthcare to discuss Q1FY27 results on July 21

Bajaj Healthcare has scheduled an earnings call to discuss its financial performance for the quarter ended June 30, 2026. The conference is set for July 21, 2026, at 4:00 PM IST, providing stakeholders a platform to review the company's Q1FY27 results.

Earnings Call Details

The announcement was made under Regulation 30 of the SEBI (LODR) Regulations, 2015. Managing Director Anil Jain and Chief Financial Officer Rohan Parekh will represent the company during the session.

Parameter	Details
Event	Q1FY27 Earnings Call
Date	July 21, 2026
Time	4:00 PM IST
Representatives	Anil Jain (MD), Rohan Parekh (CFO)

Conference Access

Participants can join the discussion via universal dial-in numbers or international toll-free lines. Pre-registration is recommended to avoid wait time.

Universal Dial In: +91 22 6280 1550 / +91 22 7115 8378

International Toll Free:

Hong Kong: 800964448
Singapore: 8001012045
UK: 08081011573
USA: 18667462133

Stakeholders may direct RSVP queries to Mr. Rohan Parekh at investors@bajajhealth.com .

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-12.47%	-6.98%	+1.75%	-10.97%	-37.76%	-10.92%

Bajaj Healthcare Limited has become the first company in India to secure a recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Cenobamate Tablets. The SEC (Neurology & Psychiatry) recommended the grant of permission for the drug in strengths of 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg. This regulatory milestone allows Bajaj Healthcare to advance the commercialization of a next-generation antiseizure medication designed for the treatment of partial-onset seizures in adults.

The intimation was filed under Regulation 30 of the SEBI (LODR) Regulations, 2015. Cenobamate offers an innovative approach to seizure management, with clinical studies demonstrating significant seizure reduction and high seizure freedom rates in patients with inadequately controlled epilepsy.

Product Details

The following table outlines the specific strengths for which the company received the recommendation:

Strength (mg)	Indication
12.5	Partial-onset seizures in adults
25	Partial-onset seizures in adults
50	Partial-onset seizures in adults
100	Partial-onset seizures in adults
150	Partial-onset seizures in adults
200	Partial-onset seizures in adults

Management Commentary

Anil Jain, Managing Director of Bajaj Healthcare Limited, stated that the approval represents a significant regulatory milestone reflecting the progress made in the development of Cenobamate Tablets. He emphasized that this reinforces the company's commitment to expanding its portfolio of differentiated Central Nervous System (CNS) therapies. The company intends to work closely with regulatory authorities to obtain necessary approvals and is positioned to manufacture and commercialize the product to strengthen its standing in the specialty pharmaceuticals segment.

Bajaj Healthcare Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), Intermediates, and Formulations. Established in 1993, the company operates manufacturing facilities catering to regulated and emerging markets, serving customers across Europe, USA, Australia, Middle East, and South America.